AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 1 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,965,528 | -37.5% | 967,527 | 0.0% | 3.05% | +9.0% |
| Q2 2023 | $15,944,845 | +23.5% | 967,527 | -31.4% | 2.80% | +4.9% |
| Q1 2023 | $12,910,186 | +173.4% | 1,409,409 | +113.7% | 2.67% | +162.6% |
| Q4 2022 | $4,721,368 | +42.9% | 659,409 | 0.0% | 1.02% | +31.9% |
| Q3 2022 | $3,304,000 | +105.3% | 659,409 | 0.0% | 0.77% | +79.5% |
| Q2 2022 | $1,609,000 | -64.3% | 659,409 | 0.0% | 0.43% | -62.2% |
| Q1 2022 | $4,504,000 | -15.5% | 659,409 | 0.0% | 1.13% | +9.7% |
| Q4 2021 | $5,328,000 | -1.0% | 659,409 | +20.1% | 1.03% | +22.4% |
| Q3 2021 | $5,383,000 | +45.6% | 549,250 | 0.0% | 0.84% | +85.3% |
| Q2 2021 | $3,696,000 | -25.6% | 549,250 | 0.0% | 0.46% | -50.2% |
| Q1 2021 | $4,965,000 | +71.1% | 549,250 | +26.5% | 0.92% | +213.7% |
| Q4 2020 | $2,901,000 | – | 434,250 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,625,000 | $12,269,000 | 3.04% |
| GENDELL JEFFREY L | 1,146,764 | $8,658,000 | 1.11% |
| Broadfin Capital, LLC | 1,029,012 | $7,769,000 | 1.04% |
| RTW INVESTMENTS, LP | 3,401,434 | $25,681,000 | 0.97% |
| BRANDES INVESTMENT PARTNERS, LP | 3,651,948 | $27,571,000 | 0.66% |
| Aristides Capital LLC | 71,520 | $540,000 | 0.42% |
| Tekla Capital Management LLC | 814,588 | $6,150,000 | 0.23% |
| INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV | 36,100 | $273,000 | 0.17% |
| Leap Investments LP | 43,481 | $328,000 | 0.15% |
| Brown Capital Management | 1,829,886 | $13,816,000 | 0.13% |